* Pfizer will cut 35 pct of R&D square footage
* Drugmaker will cut unspecified number of jobs
NEW YORK Nov 9 Pfizer Inc (PFE.N), the world's
biggest drugmaker, will close six research and development
sites and trim jobs in the United States and the United
Kingdom, following the acquisition of Wyeth.
The company on Monday said it will reduce its global
research and development square footage by 35 percent.
Pfizer will discontinue R&D operations in Princeton, New
Jersey; Chazy, Rouses Point and Plattsburgh, New York; Sanford
and Research Triangle Park, North Carolina; and Gosport,
Slough/Taplow, United Kingdom.
"While these changes are expected to bolster productivity
and reduce costs, they will result in staff reductions," Pfizer
said in a statement.
Pfizer will now conduct R&D at five main sites and nine
specialized units around the world, as compared with 20 sites
upon closing the acquisition of Wyeth.
The company did not elaborate on the number of jobs that
will be cut. A spokeswoman could not be immediately reached for
Pfizer, already the world's largest drugmaker, got much
bigger last month with completion of a $67.3 billion
acquisition of Wyeth.
(Reporting by Juan Lagorio; editing by Carol Bishopric)